RxDoctor Payments Data

Helen Adams, MD

Family Medicine · Glen Allen, VANPI 1982625463

Payments from drug & device makers

$8,707in general payments, 2019–2025

Across 565 payments — averaging $15.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$892
  • Amgen$828
  • AstraZeneca$683
  • Novo Nordisk$615
  • Boehringer Ingelheim$443
  • plus $4K from 47 others

What the payments were for

  • Consulting fees$3003%
  • Food & beverage$8,37696%
  • Education$140%
  • Entertainment$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,707 in reported general payments places this provider in the 90th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$188,017
Medicare patients
439
Services billed
3,300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban72$74,945
XifaxanRifaximin13$41,726
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$40,244
OzempicSemaglutide18$31,408
JardianceEmpagliflozin18$31,312
ProliaDenosumab18$30,608
CreonLipase/Protease/Amylase12$29,394
MyrbetriqMirabegron37$29,190
FarxigaDapagliflozin Propanediol49$29,135
JanuviaSitagliptin Phosphate19$27,689
XareltoRivaroxaban25$25,260
MounjaroTirzepatide25$24,009
RybelsusSemaglutide14$20,170
TrulicityDulaglutide11$9,295
Rosuvastatin Calcium410$5,411

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$892$74,94572 claims
Novo NordiskOzempic, Rybelsus$615$51,57832 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$51$41,72613 claims
GSKTrelegy Ellipta$421$40,24440 claims
Boehringer IngelheimJardiance, Stiolto Respimat$443$36,42529 claims
Lilly USA, LLCMounjaro, Trulicity$322$33,30436 claims
AbbVieCreon, Synthroid$1,487$31,11845 claims
AmgenProlia$828$30,60818 claims
Astellas Pharma US IncMyrbetriq$185$29,19037 claims
AstraZenecaFarxiga$683$29,13549 claims
MerckJanuvia$159$27,68919 claims
Johnson & JohnsonXarelto$217$25,26025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Glen Allen

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →